Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities
Uro-Oncology
Related content
Uro-Oncology
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
Eur Urol.
Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC, ProtecT Study Group.
doi: 10.1016/j.eururo.2019.10.030.
Uro-Oncology
Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Eur Urol.
Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK
doi: 10.1016/j.eururo.2020.02.009.
Uro-Oncology
Red and processed meat, poultry, fish and egg intakes and cause-specific and all-cause mortality among men with non-metastatic prostate cancer in a US Cohort
Cancer Epidemiol Biomarkers Prev.
Wang Y, Jacobs EJ, Shah RA, Stevens VL, Gansler T, McCullough ML
doi: 10.1158/1055-9965.EPI-19-1426.
Uro-Oncology
Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial
Eur Urol
Thurtle D, Jenkins V, Freeman A, Pearson M, Recchia G, Tamer P, Leonard K, Pharoah P, Aning J, Madaan S, Goh C, Hilman S, McCracken S, Ilie PC, Lazarowicz H, Gnanapragasam V
doi: 10.1016/j.eururo.2021.08.001
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.
Uro-Oncology
Changes in treatment and mortality in men with locally advanced prostate cancer between 2000-2016. Nationwide, population-based study in Sweden
BJU Int.
Orrason AW, Westerberg M, Garmo H, Franck Lissbrant I, Robinson D, Stattin P
doi: 10.1111/bju.15077.
Uro-Oncology
Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease
Prostate Cancer Prostatic Dis.
Sarkar RR, Patel SH, Parsons JK, Deka R, Kumar A, Einck JP, Mundt AJ, Kader AK, Kane CJ, Riviere P, McKay R, Murphy JD, Rose BS
doi: 10.1038/s41391-020-0241-3.
Uro-Oncology
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer Prostatic Dis
Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A
doi: 10.1038/s41391-021-00436-y
Uro-Oncology
Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis
JAMA Oncol.
Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D'Andrea D, John H, Shariat SF
doi: 10.1001/